Bayer Yakuhin Launches Post Menopause Osteoporosis Drug Wellnara
This article was originally published in PharmAsia News
Executive Summary
Bayer Yakuhin launched post menopause osteoporosis drug Wellnara Feb. 17, an oral combo agent of estradiol and levonorgestrel. The drug was approved in Japan in October. According to Bayer, long term use of the prevailing estrogen supplemental therapy to treat post menopause osteoporosis, unlike Wellnara, can cause the endometrium to thicken. (Click here for more - Japanese language